Sign In
Buy BMRA
$2.11
-0.0700 (-3.21%)
At Close: Jun 03, 2026
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
08:19am, Thursday, 28'th May 2026
Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream al
Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
08:19am, Wednesday, 29'th Apr 2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical exper
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claim
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
08:19am, Tuesday, 14'th Apr 2026
— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Est
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
06:57pm, Monday, 13'th Apr 2026
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products toda
Biomerica (BMRA) to Post Earnings on Monday
02:00am, Monday, 06'th Apr 2026
Biomerica (NASDAQ: BMRA - Get Free Report) is anticipated to post its results after the market closes on Monday, April 13th. Analysts expect Biomerica to post earnings of ($1.20) per share and revenue
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
08:19am, Wednesday, 18'th Mar 2026
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced it has received its first
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
08:19am, Thursday, 05'th Mar 2026
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic l
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent w
Biomerica (NASDAQ:BMRA) Stock Passes Below 200 Day Moving Average – Here’s Why
04:57am, Tuesday, 24'th Feb 2026
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.67 and traded as low as $
Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution
08:19am, Wednesday, 18'th Feb 2026
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
05:17pm, Wednesday, 14'th Jan 2026
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Com
Short Interest in Biomerica, Inc. (NASDAQ:BMRA) Expands By 123.2%
04:57am, Wednesday, 14'th Jan 2026
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 92,289 shares, a growth
Biomerica (NASDAQ:BMRA) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?
03:14am, Thursday, 25'th Dec 2025
Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $2.93 and traded as low as
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
08:19am, Tuesday, 23'rd Dec 2025
IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, today announced that the Centers for Medicare & Medicaid Services
